Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

IPC News

Displaying 1 to 10 of 66 Posts . Displaying 10 of Posts . Page of 7 . Go To Page: . Per Page: . . . View All Sort By: .
Mrowietz  Commentary

Commentary: Vaccine Hesitancy and Access to Psoriasis Care in the COVID-19 Pandemic

IPC Councilor, Ulrich Mrowietz, MD, shares his expert opinion on Cook et al (Br J Dermatol 2022 (online first)) report on the interruption of psoriasis care during the COVID-19 pandemic and vaccine hesitancy in patients with psoriasis.

Read More

Newest IPC Councilors

Three councilors join the group of IPC experts who are working to advance knowledge and enhance the care psoriasis patients around the world.

Read More

Focus on Psoriasis: A Report from the 2022 American Academy of Dermatology (AAD) Annual Meeting

The 2022 American Academy of Dermatology (AAD) Annual Meeting was held Thursday, March 24 – Tuesday, March 29 in Boston, Massachusetts. The program was packed with sessions showcasing the latest innovations in dermatology and venereology. Grace Hile, MD, has written a congress report with summaries of eleven psoriasis-focused presentations. You can download the full report or read on for a brief look at some of the highlights.

Read More

PsoProtect Registry Data Update

PsoProtect, a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis, has updated their preliminary data and now includes the first 1,525 cases.

Read More
Pincelli Commentary

Commentary: IFN-k is a rheostat for development of psoriasiform inflammation

IPC Councilor, Carlo Pincelli, MD, shares his expert opinion on innovative research that connects insights into immunopathogenesis with genetics and modes of action of treatments.

Read More

Focus on psoriasis: A report from the 2021 hybrid Gene to Clinic Congress

The Psoriasis: from Gene to Clinic International Congress provides a forum for psoriasis experts from around the world to present and discuss cutting-edge issues. You can download the full report or read a summary of some of the highlights.

Read More

New partnership announcement

IPC announces its official partnership with IFPA. Together we will work together to improve the lives of those living with psoriasis and psoriatic arthritis.

Read More

New IPC Councilors

Three councilors join the group of IPC experts who are working to advance knowledge and enhance the care psoriasis patients around the world.

Read More

FDA approves second indication for SKYRIZI®

The U.S. Food and Drug Administration (FDA) has approved a second indication for SKYRIZI® (risankizumab-rzaa) to treat adults with active psoriatic arthritis.

Read More

Commentary: Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study

IPC Councilor Arnon Cohen shares his expert opinion on a study led by IPC Board Member Catherine Smith that described humoral and cellular immunity against SARS-CoV-2 spike glycoprotein in sixty-seven patients with psoriasis compared to fifteen healthy controls after the second dose of the COVID-19 vaccine BNT162b2 (Pfizer-BioNTech).

Read More

Stay informed

Join the email list to receive the latest information on psoriasis meetings, manuscripts and research.
SUBSCRIBE

now available

COVID-19 Psoriasis Resource Center

Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve

explore now

  


IPC STATEMENT
on SARS-CoV-2 Vaccines and Psoriasis
 

Six key take-aways that physicians and other healthcare practitioners should consider when administering the SARS-CoV-2 vaccine to psoriasis patients.

READ FULL STATEMENT


We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.
OK